Dandu Biosciences Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 32.90 Cr
as on 19-12-2024
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
About Dandu Biosciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 32.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Dandu Biosciences Private Limited India is Ashwini Mangalampalle as COMPANY SECRETARY. Viswanath Toshniwal, Jeetendra Kashinath, and Joyeeta Nair serve as directors at the Company.
- CIN/LLPIN
U24290TG2021PTC156859
- Company No.
156859
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Nov 2021
- Date of AGM
16 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Dandu Biosciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashwini Mangalampalle  | Company Secretary | 01-Nov-2022 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Viswanath Toshniwal | Additional Director | 25-Oct-2024 | Current |
| Jeetendra Kashinath | Additional Director | 25-Oct-2024 | Current |
| Joyeeta Nair | Additional Director | 25-Oct-2024 | Current |
Financial Performance of Dandu Biosciences.
Dandu Biosciences Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Dandu Biosciences?
In 2022, Dandu Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Niedlfree Technologies Private LimitedActive 3 years 3 months
Viswanath Toshniwal and Jeetendra Kashinath are mutual person
- Neocell Bio-Technologies Private LimitedActive 1 year 1 month
Jeetendra Kashinath is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dandu Biosciences?
Dandu Biosciences has a workforce of 41 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dandu Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dandu Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
